NO20090262L - Galeniske formuleringer av aliskiren og hydroklorotiazid - Google Patents

Galeniske formuleringer av aliskiren og hydroklorotiazid

Info

Publication number
NO20090262L
NO20090262L NO20090262A NO20090262A NO20090262L NO 20090262 L NO20090262 L NO 20090262L NO 20090262 A NO20090262 A NO 20090262A NO 20090262 A NO20090262 A NO 20090262A NO 20090262 L NO20090262 L NO 20090262L
Authority
NO
Norway
Prior art keywords
aliskiren
hydrochlorothiazide
galenic formulations
combinations
effective amount
Prior art date
Application number
NO20090262A
Other languages
English (en)
Inventor
Matthias Willmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090262(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090262L publication Critical patent/NO20090262L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til en fast oral doseringsform omfattende en terapeutisk effektiv mengde av aliskiren, eller et farmasøytisk akseptabelt salt derav, en terapeutisk effektiv mengde av HCTZ og et hydrofilt fyllstoff valgt fra gruppen av et karbohydrat eller kombinasjoner derav, f eks. sukkere, sukkeralkoholer og stivelser eller kombinasjoner av disse.
NO20090262A 2006-06-23 2009-01-16 Galeniske formuleringer av aliskiren og hydroklorotiazid NO20090262L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds
PCT/EP2007/005476 WO2007147596A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
NO20090262L true NO20090262L (no) 2009-01-19

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090262A NO20090262L (no) 2006-06-23 2009-01-16 Galeniske formuleringer av aliskiren og hydroklorotiazid

Country Status (26)

Country Link
US (1) US8618172B2 (no)
EP (3) EP3391878A1 (no)
JP (1) JP5362556B2 (no)
KR (1) KR101442272B1 (no)
CN (1) CN101472566A (no)
AR (1) AR061565A1 (no)
AU (1) AU2007263261B2 (no)
BR (1) BRPI0713338A2 (no)
CA (1) CA2654872A1 (no)
CL (1) CL2007001837A1 (no)
EC (1) ECSP088986A (no)
ES (1) ES2704979T3 (no)
GB (1) GB0612540D0 (no)
GT (1) GT200800297A (no)
IL (1) IL195425A (no)
MA (1) MA30527B1 (no)
MX (1) MX2008016533A (no)
MY (1) MY146779A (no)
NO (1) NO20090262L (no)
NZ (1) NZ572937A (no)
PE (2) PE20120990A1 (no)
RU (1) RU2491058C2 (no)
TN (1) TNSN08528A1 (no)
TW (1) TWI457137B (no)
WO (1) WO2007147596A1 (no)
ZA (1) ZA200809773B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040373A2 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of aliskiren
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
US20100093603A1 (en) * 2008-07-17 2010-04-15 Kenneth Baker Use of organic compounds
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
CA2901802C (en) * 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
KR20080000624A (ko) * 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법
WO2007048027A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Also Published As

Publication number Publication date
ES2704979T3 (es) 2019-03-21
AU2007263261A1 (en) 2007-12-27
RU2009101971A (ru) 2010-07-27
WO2007147596A1 (en) 2007-12-27
MY146779A (en) 2012-09-28
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
GB0612540D0 (en) 2006-08-02
NZ572937A (en) 2011-11-25
ZA200809773B (en) 2009-11-25
TWI457137B (zh) 2014-10-21
EP2034968B1 (en) 2018-10-31
CL2007001837A1 (es) 2008-06-13
EP2034968A1 (en) 2009-03-18
BRPI0713338A2 (pt) 2012-03-06
KR20090021353A (ko) 2009-03-03
AU2007263261B2 (en) 2011-07-14
US8618172B2 (en) 2013-12-31
AR061565A1 (es) 2008-09-03
US20090203679A1 (en) 2009-08-13
KR101442272B1 (ko) 2014-09-22
EP2311439A1 (en) 2011-04-20
GT200800297A (es) 2009-03-09
PE20080373A1 (es) 2008-06-06
IL195425A (en) 2014-01-30
CN101472566A (zh) 2009-07-01
RU2491058C2 (ru) 2013-08-27
CA2654872A1 (en) 2007-12-27
TW200808358A (en) 2008-02-16
JP5362556B2 (ja) 2013-12-11
PE20120990A1 (es) 2012-08-16
TNSN08528A1 (en) 2010-04-14
ECSP088986A (es) 2009-01-30
EP3391878A1 (en) 2018-10-24
JP2009541239A (ja) 2009-11-26
IL195425A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
NO20090262L (no) Galeniske formuleringer av aliskiren og hydroklorotiazid
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
WO2008069921A3 (en) Oral transmucosal nicotine dosage form
NO20090141L (no) Stabiliserte, farmasøytiske preparater som omfatter fesoterodin
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IL192740A (en) Use of Sphingomyelinic Acid Pharmaceuticals for the Preparation of Medication Adapted to the Neymen-Pick A or B Disease Rooms
JP2010047612A5 (no)
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
MX2010003923A (es) Formulacion farmaceutica de valsartan.
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
JP2009531457A5 (no)
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
EP2062579A4 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING OPTICALLY STABLE RAMOSETRON
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
EP2142549A4 (en) ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
DK1994926T3 (da) Valsartanformuleringer
WO2007011958A3 (en) Intraoral dosage forms of glucagon
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2008075984A3 (en) Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents